PIK3CD and ovarian carcinoma: (Hu et al., 2020) reported that the PI3K/mTOR dual inhibitor PKI-402 not only inhibits the proliferation of the cisplatin-sensitive ovarian cancer epithelial cell line A2780 but also inhibits the proliferation of the cisplatin-sensitive ovarian cancer epithelial cell line A2780.